these data and due to clinical experience in ALA-PDT (CalzavaraPinton, 1995; Wolf et al, 1993) an ALA (hydrochloride) mixture of 20% was prepared in an ointment (Neribas ® , Schering, Berlin, Germany). Of the 20% ALA mixture, 0.2 g (40 mg ALA cm -2 ) were applied to a 1-cm 2 skin area of BCC, SCC, psoriatic lesions, and all normal skin lesions. Treated skin was covered with an occlusive foil (Tegaderm ® , 3M Healthcare, Borken, Germany), gauze, aluminium foil and tape to enhance tissue penetration and avoid photobleaching of the formed porphyrins. After defined incubation times (1, 2, 4, 6, 9, 12 and 24 h) the tape and the ointment were removed and the treated area was illuminated with Wood's light (Fluotest ® , Xenotest, Hanau, Germany; . Fluorescence intensity was measured and expressed semiquantitatively according to a fluorescence standard as 0 (no), 1 (low), 2 (medium) and 3 (strong fluorescence). The fluorescent area was marked. Basal values were obtained from untreated controls.
According to our clinical experience, BCC and SCC reveal a strong, homogeneous, ALA-induced porphyrin fluorescence under Wood's light ( Figure 1A ) (Fritsch et al, 1996a (Fritsch et al, , 1997b , whereas about 20-40% of psoriatic lesions show areas with inhomogeneous or absent fluorescence ( Figure 1B ). For better comparison of intralesional porphyrin formation in PS and tumours, we selected only uniform fluorescing psoriatic areas for our study. Biochemical analysis was also performed in nonfluorescing psoriatic areas (n = 8) which were treated with ALA for 6 h.
Preparation of skin samples
Only superficial layers of skin samples (< 1 mm) were included in the study due to the limited penetration of topically applied ALA (Szeimies et al, 1994; Martin et al, 1995; Peng et al, 1995) .
Immediately after excision tissue samples were frozen in liquid nitrogen and stored at -80°C until further examination.
Determination of total porphyrin and protein levels in tissues
Tissue samples were weighed and cut into small pieces. After homogenization with an Ultraturrax and centrifugation at 3000 U min -1 for 10 min, porphyrins were isolated with 1.0 N perchloric acid/methanol (1/1, v/v). In the supernatant, the total porphyrin level was assessed by fluorescence spectroscopy (Perkin Elmer LS-5, Überlingen, Germany); emission was recorded in a range of 520-700 nm at an excitation wavelength of 405 nm (Soret band). For quantification a protoporphyrin standard (Porphyrin Products Inc., Logan, Utah, USA) was used (Fritsch et al, 1997a) . Protein levels were determined in the pellet according to Lowry et al (1951) .
Determination of porphyrin metabolites in tissues
The supernatant was adjusted with acetic acid to pH 3-4, porphyrins were bound to talcum, esterified and metabolites were identified by HPLC with fluorescence detection (L-7480, Merck Hitachi, Darmstadt, Germany) using a porphyrin standard mixture (Porphyrin Products Inc., Logan, Utah, USA) for quantification (Seubert and Seubert, 1982) . The following metabolites were analysed: protoporphyrin, tricarboxylic porphyrin, coproporphyrin, pentacarboxylic porphyrin, hexacarboxylic porphyrin, heptacarboxylic porphyrin and uroporphyrin. The last four porphyrin metabolites are designated as highly carboxylated porphyrins; data are given as the sum of these compounds. BCC, basal cell carcinoma; SCC, squamous cell carcinoma; PS, psoriasis lesion; NS-A, normal skin adjacent to lesion; NS-D, normal skin distant from lesion; NS, normal skin in patients free of lesions. Normal skin samples were taken from patients whose tumours or psoriatic lesions were also treated by ALA. One part of these samples was adjacent to the lesions (NS-A) and one part distant to the lesions (NS-D). In addition, normal skin samples were examined in other patients which were not yet included for tumours or psoriasis (NS). Thus, the neoplastic lesions had individual and interindividual controls of normal skin. 
Fluorescence intensities of ALA-treated skin irradiated by Wood's light (370-405 nm, 10-cm distance, 5 mW cm -2 ). Values are given according to a fluorescence standard: 0 = no fluorescence, 3 = maximum fluorescence (n = 4; mean ± s.e.m.). Normal skin (NS) was observed in patients free of tumours and psoriasis. NS, BCC, SCC or PS not treated by ALA did not show any fluorescence.
Statistical calculation
Statistical analysis of the data was performed by Student's t-test. Data are reported as mean ± SEM. Changes were considered statistically significant when P < 0.05.
RESULTS

Fluorescence intensities of treated tissues
The highest macroscopic fluorescence intensities were found in BCC, SCC and PS 4-6 h after ALA application. At all time-points normal skin (NS) revealed only slight fluorescence intensities compared with neoplastic and psoriatic skin (Table 2) .
Basal total porphyrin levels in BCC, SCC, PS and skin (all)
In untreated tissues (basal values), the levels of total porphyrins were similarly low in normal skin, tumours and psoriasis ( Figure 2 ).
Total porphyrin levels in BCC, SCC, PS and skin after topical application of ALA
ALA application induced porphyrin synthesis in all tissues. The porphyrin levels in BCC and SCC showed maximum values between 2 h (53.8 ± 19.3 and 46.8 ± 17.3) and 6 h (60.0 ± 13.4 and 49.4 ± 13.1 nmol mg -1 protein). The highest porphyrin accumulation was measured in psoriatic lesions with 91.7 ± 14.4 nmol mg -1 protein at 6 h. Normal skin samples: in NS and NS-D, the accumulation of ALA-induced porphyrins was comparably low with a maximum at 24 h (15.6 ± 6.6 nmol mg -1 protein) ( Figure 2) ; at 6 h, NS-A close to tumours or PS showed higher porphyrin levels (23.8 ± 4.0 and 19.1 ± 4.1 nmol mg -1 protein) than NS or normal skin distant from lesions (NS-D). The ratio of porphyrins measured in BCC vs NS (BCC/NS) showed maximum values between 1 and 6 h (4.8-5.5) (Figure 3 ). The maximum ratio of porphyrins SCC/NS (4.8-5.1) was observed 1-4 h after ALA-application. In PS, there was the most distinct maximum of the porphyrin ratio to NS with 7.0 after 6 h. However, using normal skin adjacent to tumours of PS (NS-A) as reference, the ratios of porphyrin levels in lesions vs skin were much lower; maximum values were measured after 2 h for BCC (3.7), after 4 h for SCC (3.3) and after 6 h for PS (4.8).
Basal porphyrin metabolite levels in BCC, SCC, PS and NS (all)
The pattern of porphyrin metabolites was comparable in all untreated tissues with protoporphyrin as the predominant metabolite (82.9-92.3%) followed by uroporphyrin (all tissues) (4.6-6.2%), heptacarboxylic porphyrin (NS: 0.9% and PS: 1.5%), and coproporphyrin (BCC: 2.7% and SCC: 3.9%).
Porphyrin metabolite patterns in BCC, SCC, PS and NS (all) after topical application of ALA
The pattern of metabolites was not changed following ALA-treatment. Protoporphyrin was still the predominant metabolite and Figure 4A and B).
Only at 1 h was there a slight decrease in protoporphyrin and a slight increase in the highly carboxylated porphyrins. At the timepoint of the maximum ratio of porphyrins in BCC/NS, SCC/NS or PS/NS (1-12 h, 6 h), protoporphyrin was the prevailing metabolite in the lesions (Table 3 , Figure 4A and B).
DISCUSSION
In the present study the time course of porphyrin metabolite formation in human skin after topical application of ALA was investigated. The maximum levels of porphyrins in epithelial tumours and psoriatic lesions had already been detected at 1-6 h after application of ALA. This indicates that ALA is rapidly absorbed by the damaged skin and abnormal cells, and subsequently converted to porphyrins. In NS and NS-D, porphyrin sensitization was less than in BCC, SCC or PS but prolonged, indicating temporary skin photosensitivity. The higher porphyrin levels in NS-A than in NS (Figure 2 ) may be due to the leakage of porphyrins from the lesions into the surrounding tissues. This phenomenon may be relevant with respect to PDT efficacy because the tumour-nutrifying tissue is an additional target in therapy (Goetz et al, 1990 ).
Comparing porphyrin levels in lesions with that in NS ( Figures  2 and 3) , optimum efficacy of topical ALA-PDT may be expected if irradiation of BCC and SCC is performed between 1 and 6 h, and of PS at 6 h, after ALA treatment.
In general, the available data on ALA-induced porphyrin levels in human tissues are based on fluorescence studies Svanberg et al, 1994; Szeimies et al, 1994; Malik et al, 1995; Martin et al, 1995; Peng et al, 1995; Stringer et al, 1996) (Table 4) and only some biochemical studies were performed (Fritsch et al, 1997c (Fritsch et al, , 1998 . It was shown by fluorescence microscopy that the major factor limiting the efficacy of topical ALA-PDT is the penetration depth of ALA and ALA-induced NS 4.7 ± 0.8 88.3 ± 2.8 0 ± 0 0.6 ± 0.5 0 ± 0 0.7 ± 0.4 4.0 ± 0.9 7.9 ± 1.3 BCC 15.7 ± 1.1* 92.2 ± 1.2 0 ± 0 2.1 ± 0.6 0 ± 0 0.6 ± 0.3 1.1 ± 0.4 5.3 ± 1.3 SCC 16.7 ± 2.1* 92.6 ± 1.7 0 ± 0 1.9 ± 0.7 0 ± 0 0.4 ± 0.3 3.6 ± 1.1 7.1 ± 1.6 PS 21.9 ± 2.7* 83.8 ± 7.6 0 ± 0 1.5 ± 1.3 0.5 ± 0.4 2.1 ± 1.3 4.3 ± 2.7 8.9 ± 2.5
Data are given as nmol porphyrin g -1 protein (n = 4; mean ± s.e.m.; *P < 0.005). Porphyrin patterns showed no significant differences between tumours, psoriasis and normal skin. porphyrins, which is dependent on the incubation time of ALA, the combination with additives and the kind of skin surface treated. In the case of BCC, the penetration was limited to a depth of about 0.75-0.81 mm (Martin et al, 1995; Peng et al, 1995) and could be enhanced by addition of dimethylsulphoxide (DMSO) and ethylenediaminetetraacetic acid disodium salt (EDTA) (up to 1.25 mm). Long-time application of ALA together with 4% EDTA for 20-48 h increased the homogeneity of fluorescence distribution, particularly at the bottom of the lesions (Peng et al, 1995) .
Fluorescence studies on the kinetics of the ALA-induced porphyrins showed maximum levels in BCC and PS 4-6 h after ALA application with 3-15-fold higher levels than in normal skin (Svanberg et al, 1994; Stringer et al, 1996) . These data are supported by our analysis.
In the psoriatic skin samples which showed no fluorescence 6 h after ALA application, we found no higher porphyrin levels (22.4 ± 8.2 nmol g -1 protein) than in NS-A. The hyperkeratotic psoriatic areas with limited penetration of ALA may be one reason for the inhomogeneous accumulation of porphyrins, similarly to verrucae vulgares (Fritsch et al, 1997b) . The correlation of fluorescence intensity under Wood's light with the porphyrin levels suggests that the clinical evaluation of the fluorescence gives an orientation on superficial intralesional porphyrin levels. This method is already used in photodynamic diagnosis (PDD), a novel, effective diagnostic modality in tumour detection and demarcation (Figure 1) (Fritsch et al, 1996a (Fritsch et al, , 1997b (Fritsch et al, , 1997d Kriegmair et al, 1996) .
In the present study no striking differences between basal and ALA-induced porphyrin metabolite patterns were found with protoporphyrin as the predominant compound (Table 3) . Inhibition of mitochondrial ferrochelatase, which forms haem by incorporation of iron into protoporphyrin, might decrease haem availability for negative feedback control. This could explain the accumulation of protoporphyrin in tumour and psoriatic tissue, analogous to cells from patients who suffer from erythropoietic protoporphyria (Bloomer et al, 1977) . It might be that the normal kinetics of ferrochelatase in epithelial cells, which are most probably responsible for porphyrin synthesis in epithelial neoplasms, are rate-limiting for the entire pathway, and that by supplying an overwhelming quantity of upstream substrate (ALA), protoporphyrin is predominantly accumulated.
The route of ALA administration and the presence of serum proteins may be relevant for increased formation of additional porphyrins such as copro-and uroporphyrin, which was demonstrated in a hamster melanoma (Fritsch et al, 1997a) , in skin organ cultures (keratoakanthoma, BCC and NS) (Fritsch et al, 1997c) and various cell lines incubated with FCS-containing medium (Hanania et al, 1992; Bolsen et al, 1996) .
In the case of topical ALA-application, the accumulation of higher levels of total porphyrins in tumours and psoriasis lesions appears to be the major effect responsible for the intralesional photosensitization. Our biochemical data show that the porphyrin metabolite patterns are not significantly changed upon ALA treatment.
Intravenous injection or oral administration of ALA was shown to optimize the homogeneous intralesional accumulation of porphyrins in PS, BCC and oral cavity SCC (Grant et al, 1993; Peng et al, 1995; Stringer et al, 1996) . In mice or rats bearing colon or mammary carcinomas and in hamsters bearing an amelanotic melanoma, systemically administered ALA led to earlier (1 h) and higher tumour/skin ratios (6-30) of porphyrins than did topical ALA application Hua et al, 1995; Sroka et al, 1996; Fritsch et al, 1997a) . However, prolonged accumulation of porphyrins in the liver following intravenous injection of ALA was detected (Fritsch et al, 1997a) which may be responsible for reported side effects such as nausea, vomiting or transient increases in serum aspartate aminotransferase (Regula et al, 1994; Peng et al, 1995) . Thus, topical application of ALA seems to be still the most promising technique in PDT of epithelial skin tumours due to lack of severe side effects (Fritsch et al, 1996b) . PDT efficacy may be enhanced using ALA esters (Fritsch et al, 1998) .
After topical application of ALA (for PDD or PDT), light avoidance for 2 days is recommended due to the prolonged porphyrin sensitization of normal skin, which lasts up to 48 h with decreasing intensity (data not shown). Psoriatic lesions may not offer *, Subcutaneously growing tumours; Ca, carcinoma; Pre-treatment levels, time-point after ALA-application which was reported to show comparable porphyrin levels prior to ALA treatment; LIF, laser-induced fluorescence analysis; FM, fluorescence microscopy F, fluorescence detection under excitation with UV/visible light; SP, spectrophotometry of extracted porphyrins; HPLC, high performance liquid chromatography; n.d. = no data.
optimum conditions for topical ALA-PDT and should be selected according to the fluorescence pattern under Wood's light.
ABBREVIATIONS
ALA, δ-aminolaevulinic acid; BCC, basal cell carcinoma; DMSO, dimethylsulphoxide; EDTA, ethylenediaminetetraacetic acid; NS, normal skin; NS-A, normal skin adjacent to tumour or psoriasis lesion; NS-D, normal skin distant from tumour or psoriasis lesion; PDD, photodynamic diagnosis; PDT, photodynamic therapy; PS, psoriasis; SCC, squamous cell carcinoma
